Equities Analysts Issue Forecasts for DNTH FY2026 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Dianthus Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings of ($3.44) per share for the year. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Monday, May 12th. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.81 million.

A number of other brokerages also recently commented on DNTH. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Guggenheim reaffirmed a “buy” rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Finally, Robert W. Baird reduced their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $53.00.

Dianthus Therapeutics Price Performance

Shares of DNTH stock opened at $18.75 on Tuesday. The firm’s 50-day moving average is $18.94 and its two-hundred day moving average is $21.21. Dianthus Therapeutics has a 12 month low of $13.37 and a 12 month high of $32.27. The company has a market capitalization of $603 million, a PE ratio of -7.50 and a beta of 1.36.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Octagon Capital Advisors LP raised its stake in shares of Dianthus Therapeutics by 11.0% in the 1st quarter. Octagon Capital Advisors LP now owns 2,341,667 shares of the company’s stock valued at $42,478,000 after acquiring an additional 231,500 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after acquiring an additional 618 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of Dianthus Therapeutics by 5.0% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 189,000 shares of the company’s stock valued at $3,428,000 after acquiring an additional 9,000 shares during the period. ADAR1 Capital Management LLC raised its stake in shares of Dianthus Therapeutics by 3.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 18,285 shares of the company’s stock valued at $332,000 after acquiring an additional 602 shares during the period. Finally, Vestal Point Capital LP raised its stake in shares of Dianthus Therapeutics by 58.1% in the 1st quarter. Vestal Point Capital LP now owns 1,700,069 shares of the company’s stock valued at $30,839,000 after acquiring an additional 625,069 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.